Testing a new cancer immunotherapy in advanced solid tumors
Part of Cancer clinical trials.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 with a diagnosed advanced or recurrent solid tumor that hasn't responded to standard treatments or for which no approved treatment exists
- Tumor tissue sample available (fresh or archived) showing PD-L1 protein expression (required in Phase 1b; may not be required in Phase 1a for certain tumor types)
- At least one measurable tumor lesion visible on imaging
- Good overall health (ECOG Performance Status 0–1) with life expectancy of at least 3 months
- Normal organ function (blood, liver, kidney, heart tests) and able to use effective contraception for 6 months after the study
- No serious infections, no other active cancers, no recent major surgery, and no uncontrolled heart disease or brain tumors
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a combination of two investigational drugs (IMM2510 and IMM01) that work with your immune system to fight cancer. It may help people with advanced solid tumors who have not responded to other treatments.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.